These features are known to be essential to tumor progression.

This gene is thought to play a role in tumor progression.

All nine patients died, eight due to tumor progression.

We do not have data that tumor progression is an issue as a result of erythropoietin treatment.

Clinical trials have reported that the median time from tumour progression to death is usually very short, between 1 and 4.5 months.

All patients except one died of tumor progression.

Thus, c-Src plays a key role in the tumor progression of breast cancers.

HIF-1, a transcription factor is known to play a major role in tumor progression.

The role of centrosomes in tumor progression is unclear.

The stage IV patients died 6-18 months after diagnosis from tumour progression.